Literature DB >> 25348149

Optimal use of pegvisomant in acromegaly: are we getting there?

Andrea Giustina1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348149     DOI: 10.1007/s12020-014-0462-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  58 in total

1.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

Review 2.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

3.  Somatostatin analog withdrawal in patients with acromegaly: an elusive goal?

Authors:  Moisés Mercado
Journal:  Endocrine       Date:  2014-04-16       Impact factor: 3.633

4.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

Review 5.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

Review 6.  Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

Authors:  Patrick Maison; Anne-Isabelle Tropeano; Isabelle Macquin-Mavier; Andrea Giustina; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

7.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors:  Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

8.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.

Authors:  Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert F Gagel; Philip E Harris; Peter J Trainer; Aart Jan van der Lely; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2005-08-02       Impact factor: 5.958

Review 9.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

10.  Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.

Authors:  Lucio Vilar; Maria Fleseriu; Luciana Ansaneli Naves; José Luciano Albuquerque; Patrícia Sampaio Gadelha; Manuel dos Santos Faria; Gilvan Cortês Nascimento; Renan Magalhães Montenegro; Renan Magalhães Montenegro
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

View more
  10 in total

1.  How to improve effectiveness of pegvisomant treatment in acromegalic patients.

Authors:  M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo
Journal:  J Endocrinol Invest       Date:  2017-10-28       Impact factor: 4.256

2.  Medical treatment of acromegaly in pregnancy, highlights on new reports.

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

3.  Fabula (non) acta est….Endocrine.

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2018-12       Impact factor: 3.633

4.  Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment.

Authors:  S Chiloiro; M Mormando; A Bianchi; A Giampietro; D Milardi; C Bima; G Grande; A M Formenti; G Mazziotti; A Pontecorvi; A Giustina; L De Marinis
Journal:  Endocrine       Date:  2017-08-23       Impact factor: 3.633

5.  Daily life reflections of acromegaly guidelines.

Authors:  T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2016-10-20       Impact factor: 4.256

6.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 7.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

8.  Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.

Authors:  Caroline Sievers; Dorothee M Baur; Anja Schwanke; Michael Buchfelder; Michael Droste; Klaus Mann; Günter K Stalla
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 9.  Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age.

Authors:  Silvana Duran-Ortiz; Edward O List; Reetobrata Basu; John J Kopchick
Journal:  Pituitary       Date:  2021-01-18       Impact factor: 4.107

Review 10.  Pegvisomant in acromegaly: an update.

Authors:  A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2017-02-07       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.